Benefit of single-injection Depot Progesterone before surgery in node positive breast cancer patients
•
0 gostou•224 visualizações
![Editoriale Page 1 of 1
Benefit of single-injection Depot Progesterone before surgery in node positive
breast cancer patients
This is the first randomized evidence suggesting benefit of short-term peri-operative
hormone therapy (progesterone) in DFS and OS in node positive breast cancer. The results
not only suggest an easily implementable cost-effective intervention in routine clinical
practice but also offers some biological insights about when does metastases set in? and how
modulation of events at the time of surgery affects a chronic disease?. In absence of side
effects and low cost of intervention this would be the most effective intervention for the
developing world as well as cash strapped health care systems globally. The results need to
be reproduced in other parts of the world.
Bibliographic Reference:
Badwe R et al.: "Single-Injection Depot Progesterone Before Surgery and Survival in Women
With Operable Breast Cancer: A Randomized Controlled Trial", J Clin Oncol. 2011 Jun 13.
[Epub ahead of print]
Raj Badwe
Tata Memorial Hospital, Mumbai, India
http://www.senology.org/Edit_Badwe.htm 09/09/2011](https://image.slidesharecdn.com/editbadwe-110909083203-phpapp02/85/Benefit-of-single-injection-Depot-Progesterone-before-surgery-in-node-positive-breast-cancer-patients-1-320.jpg)
Recomendados
Recomendados
Mais conteúdo relacionado
Mais procurados
Mais procurados (8)
Destaque
Destaque (9)
Semelhante a Benefit of single-injection Depot Progesterone before surgery in node positive breast cancer patients
Semelhante a Benefit of single-injection Depot Progesterone before surgery in node positive breast cancer patients (20)
Mais de Senology.org
Mais de Senology.org (20)
Último
Último (20)
Benefit of single-injection Depot Progesterone before surgery in node positive breast cancer patients
- 1. Editoriale Page 1 of 1 Benefit of single-injection Depot Progesterone before surgery in node positive breast cancer patients This is the first randomized evidence suggesting benefit of short-term peri-operative hormone therapy (progesterone) in DFS and OS in node positive breast cancer. The results not only suggest an easily implementable cost-effective intervention in routine clinical practice but also offers some biological insights about when does metastases set in? and how modulation of events at the time of surgery affects a chronic disease?. In absence of side effects and low cost of intervention this would be the most effective intervention for the developing world as well as cash strapped health care systems globally. The results need to be reproduced in other parts of the world. Bibliographic Reference: Badwe R et al.: "Single-Injection Depot Progesterone Before Surgery and Survival in Women With Operable Breast Cancer: A Randomized Controlled Trial", J Clin Oncol. 2011 Jun 13. [Epub ahead of print] Raj Badwe Tata Memorial Hospital, Mumbai, India http://www.senology.org/Edit_Badwe.htm 09/09/2011